Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Bellicum Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Bellicum Pharmaceuticals Inc market cap is $889,600.00.
What is the 52-week high for Bellicum Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Bellicum Pharmaceuticals Inc 52 week high is $1.31 as of September 28, 2025.
What is the 52-week low for Bellicum Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Bellicum Pharmaceuticals Inc 52 week low is $0.06 as of September 28, 2025.
What is Bellicum Pharmaceuticals Inc stock price today?
Bellicum Pharmaceuticals Inc stock price today is $0.0748.
What was Bellicum Pharmaceuticals Inc stock price yesterday?
Bellicum Pharmaceuticals Inc stock price yesterday was $0.0801.
What is the PE ratio of Bellicum Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Bellicum Pharmaceuticals Inc’s P/E ratio is -0.06.
What is the Price-to-Book ratio of Bellicum Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Bellicum Pharmaceuticals Inc P/B ratio is -0.0269.
What is Bellicum Pharmaceuticals Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Bellicum Pharmaceuticals Inc's EBITDA is -1.51.
What is the 50-day moving average of Bellicum Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Bellicum Pharmaceuticals Inc 50-day moving average is $0.1088.